GlaxoSmithKline PLC and Pfizer Inc agreed to combine their consumer healthcare businesses in a joint venture controlled by the British pharmaceutical giant, paving the way for it to split into two companies.
Glaxo is to hold 68 percent of the new entity, which would have combined sales of US$12.7 billion.
The UK drugmaker said it plans to list the new business on the stock market within three years.
Glaxo shares surged as much as 5.7 percent in London trading, the most since March.
The transaction creates the world’s biggest supplier of over-the-counter medicines with brands of painkillers such as Advil and Panadol, and marks a shift from CEO Emma Walmsley’s stated strategy of keeping the steadily performing consumer and vaccine businesses under the same roof as the more volatile pharma operations.
The company yesterday said the deal sets a foundation to create two companies — one focused on pharma and vaccines, and the other on consumer health.
Glaxo, Pfizer and others are grappling with surging research costs to develop new medicines even as insurers and governments demand lower prices for the finished product. A separation would help focus resources on separate businesses with different needs.
Walmsley has been working to revitalize a lackluster pipeline of new drugs at Glaxo, culling programs to focus on those that look most likely to succeed and bringing in industry veteran Hal Barron to oversee research.
Earlier this month, Glaxo agreed to buy drugmaker Tesaro Inc for US$5.1 billion, expanding in cancer medicines for a price analysts deemed high.
The deal follows a move by Glaxo earlier this year to pay US$13 billion for Novartis AG’s stake in a consumer joint venture.
The enlarged company is to operate under the name GSK Consumer Healthcare and the Glaxo unit’s existing CEO, Brian McNamara, and its chief financial officer, Tobias Hestler, would assume those roles in the joint venture.
The transaction is expected to close in the second half of next year. After that, Pfizer said it plans to deconsolidate its share of the business, which might boost its operating margins.
The domestic unit of the Chinese-owned, Dutch-headquartered chipmaker Nexperia BV will soon be able to produce semiconductors locally within China, according to two company sources. Nexperia is at the center of a global tug-of-war over critical semiconductor technology, with a Dutch court in February ordering a probe into alleged mismanagement at the company. The geopolitical tussle has disrupted supply chains, with some carmakers reportedly forced to cut production due to chip shortages. Local production would allow Nexperia’s domestic arm, Nexperia Semiconductors (China) Ltd (安世半導體中國), to bypass restrictions in place since October on the supply of silicon wafers — etched with tiny components to
Singapore-based ride-hailing and delivery giant Grab Holdings Ltd has applied for regulatory approval to acquire the Taiwan operations of Germany-based Delivery Hero SE's Foodpanda in a deal valued at about US$600 million. Grab submitted the filing to the Fair Trade Commission on Friday last week, with the transaction subject to regulatory review and approval, the company said in a statement yesterday. Its independent governance structure would help foster a healthy and competitive market in Taiwan if the deal is approved, Grab said. Grab, which is listed on the NASDAQ, said in the filing that US-based Uber Technologies Inc holds about 13 percent of
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday received government approval to deploy its advanced 3-nanometer (3nm) process at its second fab currently under construction in Japan, the Ministry of Economic Affairs said in a news release. The ministry green-lit the plan for the facility in Kumamoto, which is scheduled to start installing equipment and come online in 2028 with a monthly production capacity of 15,000 12-inch wafers, the ministry said. The Department of Investment Review in June 2024 authorized a US$5.26 billion investment for the facility, slated to manufacture 6- to 12nm chips, significantly less advanced than 3nm process. At a meeting with
Taiwan’s food delivery market could undergo a major shift if Singapore-based Grab Holdings Ltd completes its planned acquisition of Delivery Hero SE’s Foodpanda business in Taiwan, industry experts said. Grab on Monday last week announced it would acquire Foodpanda’s Taiwan operations for US$600 million. The deal is expected to be finalized in the second half of this year, with Grab aiming to complete user migration to its platform by the first half of next year. A duopoly between Uber Eats and Foodpanda dominates Taiwan’s delivery market, a structure that has remained intact since the Fair Trade Commission (FTC) blocked Uber Technologies Inc’s
RSS